Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Latest Financial Results

Q3 2024

Quarter Ended Dec 31, 2023

Latest Annual Filing

Fiscal Year Ended Mar 31, 2023

View Filing

Stock Information

Company Overview

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.

The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

Investor Presentation - January 2024

Investor Presentation - January 2024

Download Investor Presentation - January 2024


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Acasti Pharma Inc.
103 Carnegie Center
Suite 300
Princeton , NJ 08540
685 US Highway One
North Brunswick , NJ 08902

Investor Relations

LifeSci Advisors
Mike Moyer
Managing Director
T: 617-308-4306

Transfer Agent

Computershare Trust Company of Canada
650 de Maisonneuve West
7th Floor
Montreal, QC H3A 3T2
T: 514-982-7888